Biologic and small-molecule therapy for treating moderate to severe atopic dermatitis: Mechanistic considerations - 04/07/24
Abstract |
Atopic dermatitis (AD) is a complex and heterogeneous skin disease for which achieving complete clinical clearance for most patients has proven challenging through single cytokine inhibition. Current studies integrate biomarkers and evaluate their role in AD, aiming to advance our understanding of the diverse molecular profiles implicated. Although traditionally characterized as a TH2-driven disease, extensive research has recently revealed the involvement of TH1, TH17, and TH22 immune pathways as well as the interplay of pivotal immune molecules, such as OX40, OX40 ligand (OX40L), thymic stromal lymphopoietin, and IL-33. This review explores the mechanistic effects of treatments for AD, focusing on mAbs and Janus kinase inhibitors. It describes how these treatments modulate immune pathways and examines their impact on key inflammatory and barrier biomarkers.
Le texte complet de cet article est disponible en PDF.Key words : Atopic dermatitis, molecular biomarkers, biologics, JAK inhibitors, small-molecule antagonists, targeted treatment
Abbreviations used : AD, DC, DPP-4, EASI, FCH, FLG, JAK, LOR, MMP12, SCORAD, STAT, TCS, TSLP
Plan
Vol 154 - N° 1
P. 20-30 - juillet 2024 Retour au numéro
Article précédent
- Interactions between skin-resident dendritic and Langerhans cells and pain-sensing neurons
- Natalie C. Wilcox, Golnar Taheri, Katherine Halievski, Sebastien Talbot, Jaqueline R. Silva, Nader Ghasemlou
- Exploring the skin microbiome in atopic dermatitis pathogenesis and disease modification
- Claudia Hülpüsch, Robin Rohayem, Matthias Reiger, Claudia Traidl-Hoffmann
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?